Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Change in Accured Expenses came in at $1.1 million in Q1 2026, up 436.05% year-on-year from $209877.6 in Q1 2025, and up 514.37% quarter-over-quarter from -$271503.8 in Q4 2025.

Oculis Holding AG (OCS) Change in Accured Expenses (2022 - 2026) Analysis & Trends

Oculis Holding AG's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses rose 436.05% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was -$832893.9, a 105.56% decrease from a year earlier, with the FY2025 full-year figure at -$2.3 million, down 121.96% from the prior year.
  • Change in Accured Expenses grew to $1.1 million in Q1 2026 per OCS's latest filing, from -$271503.8 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.7 million in Q2 2024 and bottomed at -$5.8 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $890610.0 (2023), against an average of $275292.4.
  • Across the five-year window, Change in Accured Expenses plunged 142.73% in 2025 and surged 436.05% in 2026, its largest moves.
  • Year by year, Change in Accured Expenses stood at $2.5 million in 2022, then plunged by 64.62% to $890610.0 in 2023, then jumped by 312.08% to $3.7 million in 2024, then sank by 107.4% to -$271503.8 in 2025, then surged by 514.37% to $1.1 million in 2026.
  • Per Business Quant, the three latest OCS Change in Accured Expenses figures stand at $1.1 million (Q1 2026), -$271503.8 (Q4 2025), and $1.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 1.13 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 931,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -16.82 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 23.10 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 107.70 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -16.74 Mn
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -176.03 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.13 Mn
Mar 31, 2026 1.13 Mn
Dec 31, 2025 -271,503.84
Dec 31, 2025 -271,503.84
Sep 30, 2025 1.17 Mn
Sep 30, 2025 1.17 Mn
Jun 30, 2025 -2.86 Mn
Jun 30, 2025 -2.86 Mn
Mar 31, 2025 -334,787.41
Mar 31, 2025 -334,787.41
Dec 31, 2024 3.67 Mn
Dec 31, 2024 3.67 Mn
Sep 30, 2024 4.95 Mn
Sep 30, 2024 4.95 Mn
Jun 30, 2024 6.69 Mn
Jun 30, 2024 6.69 Mn
Mar 31, 2024 -4.76 Mn
Mar 31, 2024 -4.76 Mn
Dec 31, 2023 890,610.03
Dec 31, 2023 890,610.03